IDEAYA Biosciences Inc. Stock News

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and de

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its plans for a clinical data update on…

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and de

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has received a consensus recommendation of Buy from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that []

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Research analysts at Oppenheimer decreased their FY2021 earnings per share estimates for shares of IDEAYA Biosciences in a research note issued on Monday, November 15th. Oppenheimer analyst K. Degeeter now forecasts that the company will earn ($1.24) per share for the year, down from their previous estimate of ($1.22). Oppenheimer []

Wall Street analysts forecast that IDEAYA Biosciences, Inc. (NASDAQ:IDYA) will announce earnings of ($0.31) per share for the current quarter, Zacks reports. Six analysts have made estimates for IDEAYA Biosciences earnings, with the lowest EPS estimate coming in at ($0.59) and the highest estimate coming in at ($0.04). IDEAYA Biosciences posted earnings of ($0.18) per []

IDEAYA Biosciences (NASDAQ:IDYA) announced its quarterly earnings results on Monday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.01), MarketWatch Earnings reports. IDEAYA Biosciences had a negative net margin of 84.49% and a negative return on equity of 13.85%. NASDAQ IDYA opened at $23.37 on []

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and dev

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and d

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -371.43% and -12.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and de

SOUTH SAN FRANCISCO, Calif., Aug. 2, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve

SOUTH SAN FRANCISCO, Calif., July 12, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common st

SOUTH SAN FRANCISCO, Calif., July 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock